Daniel Markowitz

Stock Analyst at Evercore ISI Group

(1.64)
# 3,399
Out of 5,163 analysts
30
Total ratings
26.09%
Success rate
-5.27%
Average return

Stocks Rated by Daniel Markowitz

Natera
Feb 27, 2026
Maintains: Outperform
Price Target: $250$260
Current: $187.85
Upside: +38.41%
TransMedics Group
Feb 25, 2026
Maintains: Outperform
Price Target: $155$170
Current: $123.48
Upside: +37.67%
Repligen
Feb 25, 2026
Maintains: Outperform
Price Target: $180$170
Current: $114.20
Upside: +48.86%
Guardant Health
Feb 20, 2026
Maintains: In-Line
Price Target: $105$110
Current: $85.49
Upside: +28.67%
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $370$340
Current: $219.84
Upside: +54.66%
Bio-Techne
Feb 5, 2026
Maintains: In-Line
Price Target: $62$68
Current: $50.85
Upside: +33.73%
West Pharmaceutical Services
Feb 3, 2026
Maintains: Outperform
Price Target: $390$320
Current: $235.46
Upside: +35.90%
Rambus
Feb 3, 2026
Maintains: Outperform
Price Target: $126$119
Current: $94.01
Upside: +26.58%
DexCom
Nov 25, 2025
Initiates: In-Line
Price Target: $68
Current: $64.24
Upside: +5.85%
Inspire Medical Systems
Oct 7, 2025
Maintains: Outperform
Price Target: $150$125
Current: $58.62
Upside: +113.24%